Beijing NMPA office published Beijing In Vitro Diagnostics Inspection Plan on August 1, specifying the requirements in upcoming inspections, from today, August 16, to October 11, for all IVD manufacturers.
Below are 13 points, mentioned in the Plan, that manufacturers must check:
China Med Device, LLC can help you with inspection gap analysis, onsite support during inspection and address of open issues and communication of post-inspection, etc. We are also experienced in handing IVD products. For GMP inquiries or reference letters from IVD manufacturers, please email info@ChinaMedDevice.com.
From Aug 1-Aug 16, manufacturers have the opportunity for self-audit. They can conduct retrospective audit for the authenticity, based on the submission materials, and the Corrective Actions related to the previous inspection. The reference guideline is Good Manufacturing Practice Guidelines for Onsite Inspection of In Vitro Diagnostics.
IVD companies with large sales volume have been put into priority monitoring for which intensified and unannounced inspections can be expected.
The Beijing inspection plan came after National NMPA’s 2019 Inspection Plan announced in March. National Plan involves following IVDs:
ChinaMed Device, LLC (www.ChinaMedDevice.com) provides regulatory and commercialization turnkey solutions for medical device, IVD, CDx and combination products in China. As a qualified NMPA (CFDA) legal agent with offices in Boston and Beijing, we can represent manufacturers for the complete product life cycle without their need to create a local entity in China. Our NMPA (CFDA) regulatory services include strategy, registration, local type testing, product technical requirement (PTR), clinical evaluation report (CER), clinical trial, GMP and post-market surveillance (AE, recall, inspection, etc.). Our commercialization services include market research, reimbursement, partnership strategy and distribution qualification.